Invivyd: Boral Capital Raises PT to $3, Maintains Buy Rating

Invivyd: Boral Capital Raises PT to $3, Maintains Buy Rating

Boral Capital has revised its price target for Invivyd, Inc. (NASDAQ: IVVD) to $3.00, maintaining a Buy rating. The update comes amidst positive developments in the company's pipeline and recent earnings reports. Boral Capital's analysts believe that Invivyd's lead product candidate, adintrevimab, has strong potential for treating and preventing coronavirus disease, as well as other infectious diseases [1].

Invivyd's stock has shown resilience, with a 18% increase in the past three months, driven by positive clinical trial results and strategic partnerships. The company's collaboration with Adimab and the Scripps Research Institute has further bolstered its research capabilities and product development pipeline [2].

Invivyd's earnings are expected to grow from ($1.87) to ($0.72) per share in the coming year, although the company's negative earnings and P/E ratio cannot be directly compared to companies with positive earnings. The company's P/B ratio of 0.50 suggests that it may be undervalued relative to its assets and liabilities [3].

Boral Capital's updated price target and rating reflect the company's strong pipeline, strategic partnerships, and recent positive clinical trial results. Investors should closely monitor Invivyd's upcoming earnings reports and clinical trial data for further insights into the company's growth prospects.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/IVVD/
[2] https://www.marketbeat.com/stocks/NASDAQ/IVVD/
[3] https://www.marketbeat.com/stocks/NASDAQ/IVVD/